CA2699702C - Cancer marker and therapeutic target - Google Patents

Cancer marker and therapeutic target Download PDF

Info

Publication number
CA2699702C
CA2699702C CA2699702A CA2699702A CA2699702C CA 2699702 C CA2699702 C CA 2699702C CA 2699702 A CA2699702 A CA 2699702A CA 2699702 A CA2699702 A CA 2699702A CA 2699702 C CA2699702 C CA 2699702C
Authority
CA
Canada
Prior art keywords
ccr4
tumour
cells
cancer
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2699702A
Other languages
English (en)
French (fr)
Other versions
CA2699702A1 (en
Inventor
Frances Balkwill
Violet Slettenaar
Julia Wilson
Yaohe Wang
Tiziana Schioppa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2699702(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of CA2699702A1 publication Critical patent/CA2699702A1/en
Application granted granted Critical
Publication of CA2699702C publication Critical patent/CA2699702C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/575—
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2699702A 2007-09-18 2008-09-18 Cancer marker and therapeutic target Expired - Fee Related CA2699702C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
GB0718167.0 2007-09-18
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Publications (2)

Publication Number Publication Date
CA2699702A1 CA2699702A1 (en) 2009-03-26
CA2699702C true CA2699702C (en) 2018-03-06

Family

ID=38670078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699702A Expired - Fee Related CA2699702C (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Country Status (11)

Country Link
US (2) US9134293B2 (enExample)
EP (3) EP2535716B1 (enExample)
JP (2) JP5774309B2 (enExample)
AU (1) AU2008300413B2 (enExample)
CA (1) CA2699702C (enExample)
DK (3) DK2176664T3 (enExample)
ES (3) ES2588507T3 (enExample)
GB (1) GB0718167D0 (enExample)
PL (3) PL2176664T3 (enExample)
RU (2) RU2529797C2 (enExample)
WO (1) WO2009037454A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
EP2580348B1 (en) * 2010-06-14 2018-04-25 Qiagen GmbH Method for determination of target cells or tissue for extraction of biomolecules from non-formalin-fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
WO2013063130A1 (en) * 2011-10-24 2013-05-02 Metasignal Therapeutics Inc. Carbonic anhydrase ix-related markers and use thereof
PL2785692T3 (pl) 2011-12-01 2018-02-28 Chemocentryx, Inc. Podstawione aniliny jako antagoniści ccr(4)
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
SI3065774T1 (sl) * 2013-11-06 2021-11-30 Janssen Biotech, Inc. Protitelesa proti CCL17
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
RU2740254C2 (ru) * 2014-10-01 2021-01-12 Сфинготек Гмбх ОПРЕДЕЛЕНИЕ hGH ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ТЯЖЕЛОГО НЕБЛАГОПРИЯТНОГО СЕРДЕЧНО-СОСУДИСТОГО ЯВЛЕНИЯ ИЛИ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ У ИНДИВИДУУМА
EP3283886B1 (en) * 2015-04-17 2020-01-15 Eisai Inc. Methods for treating lung cancer
WO2017017283A1 (en) 2015-07-30 2017-02-02 Qiagen Gmbh Method of preparing a frozen biological sample
TW202134282A (zh) 2015-12-02 2021-09-16 美商艾吉納斯公司 抗體和使用彼之方法
EP3626269A4 (en) 2017-05-19 2021-03-03 Shingo Maeda METHOD FOR INFILTRATION OF REGULATORY T-CELLS USING CCR4 INHIBITION AND METHOD FOR TREATMENT OF NEOPLASTIC DISEASES IN DOGS
SG11202101454PA (en) 2018-08-29 2021-03-30 Chemocentryx Inc Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JPH08507927A (ja) * 1993-03-19 1996-08-27 ザ・ジョーンズ・ホプキンス・ユニバーシティ Ａｐｃ遺伝子の変異決定用抗体およびアッセイ
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
DE60134962D1 (de) 2000-03-03 2008-09-04 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
EP1326617B9 (en) 2000-10-18 2006-10-25 Schering Aktiengesellschaft Use of 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2-pentafluoroethyl)estra-4,9-dien-3-one for the preparation of a medicament for the treatment fo breast, ovarian, endometrial cancer, myeloma and meningioma
US20020182624A1 (en) * 2001-02-28 2002-12-05 Eos Biotechnology, Inc. Chemokine receptors and disease
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
US20050101530A1 (en) 2001-08-10 2005-05-12 Topigen Pharmaceutique, Inc. Cellular virus receptors and methods of use
WO2003018635A1 (fr) 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Anticorps greffes cdr humains et fragments de ces anticorps
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
AU2003291549A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
JPWO2005035582A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 Ｃｃｒ４に特異的に結合する抗体組成物
AU2004294842B2 (en) 2003-12-04 2010-05-13 Kyowa Kirin Co., Ltd. Medicine containing genetically modified antibody against chemokine receptor CCR4
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1984501B1 (en) 2006-02-14 2011-05-18 Noxxon Pharma AG Mcp-i binding nucleic acids
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
PL2535716T3 (pl) 2017-06-30
EP2176664A2 (en) 2010-04-21
WO2009037454A3 (en) 2009-05-07
DK2535716T3 (en) 2017-02-13
US10261099B2 (en) 2019-04-16
EP2535716B1 (en) 2016-11-02
PL2533047T3 (pl) 2016-11-30
EP2176664B1 (en) 2013-11-06
RU2010123921A (ru) 2011-12-20
GB0718167D0 (en) 2007-10-31
RU2014128513A (ru) 2016-02-10
EP2535716A3 (en) 2013-03-13
RU2529797C2 (ru) 2014-09-27
EP2533047A1 (en) 2012-12-12
DK2176664T3 (da) 2014-01-20
EP2535716A2 (en) 2012-12-19
ES2443541T3 (es) 2014-02-19
EP2533047B1 (en) 2016-05-11
JP6234967B2 (ja) 2017-11-22
ES2612690T3 (es) 2017-05-18
PL2176664T3 (pl) 2014-04-30
WO2009037454A2 (en) 2009-03-26
US20100278844A1 (en) 2010-11-04
US20160223572A1 (en) 2016-08-04
JP5774309B2 (ja) 2015-09-09
AU2008300413A1 (en) 2009-03-26
JP2015212703A (ja) 2015-11-26
AU2008300413B2 (en) 2014-09-11
US9134293B2 (en) 2015-09-15
CA2699702A1 (en) 2009-03-26
DK2533047T3 (en) 2016-08-22
ES2588507T3 (es) 2016-11-03
JP2010539508A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
CA2699702C (en) Cancer marker and therapeutic target
Zhao et al. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Scala et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma
Agaimy et al. HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology
Palou et al. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin
CN102667484A (zh) 识别黑素瘤肿瘤细胞的生物标记
JP2013520958A (ja) 上皮間葉転換のバイオマーカーとしてａｘｌを使用する方法
EP2805166B1 (en) Method for the prognosis of survival time of a patient suffering from a solid cancer
Holm et al. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence
Wang et al. Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer
JP2020040959A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
Hermida-Prado et al. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Frolova et al. A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers
Kim et al. Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast with Clinicopathologic Features and T-Cell Infiltration
AU2013203369B2 (en) Cancer marker and therapeutic target
JP5145549B2 (ja) 腫瘍マーカー
Yokouchi et al. Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer
JP2019518970A (ja) 腎臓癌を患う対象の癌治療に対する感受性を予測するための方法およびキット
Pagano The potential role of CXCR4 and SDF-1 as indicators of tumor aggressiviness in patients with conventional papillary thyroid carcinoma
Devictor et al. cytochemical Assays of P-glycoprotein in Breast
Klintrup Inflammation and invasive margin in colorectal cancer
DeRycke S100A1 and nectin 4 biomarkers in ovarian cancer
Musrap Proteomic Identification of Mediators Implicated in the Metastatic Progression of Ovarian Cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130912

MKLA Lapsed

Effective date: 20210920